Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996150 | 0.89 | TYMP (0.53) | TYMPADORA1 | |
| SCHEMBL2483147 | 0.88 | TYMP (0.56) | TYMPADORA2BADORA1ADORA2AP2RY12 | |
| SCHEMBL26631290 | 0.85 | TYMP (0.50) | TYMPADORA2BADORA1ADORA2AP2RY12 | |
| SCHEMBL26631288 | 0.85 | TYMP (0.50) | TYMPADORA2BADORA1ADORA2AP2RY12 | |
| SCHEMBL6899475 | 0.82 | TYMP (0.56) | TYMPADORA2BADORA1ADORA2AP2RY12 | |
| SCHEMBL18950649 | 0.82 | ADORA3 (0.46) | ADORA3ADORA1P2RY12 | |
| SCHEMBL6898807 | 0.81 | TYMP (0.55) | TYMPADORA2BADORA1ADORA2AP2RY12 | |
| SCHEMBL6900160 | 0.81 | TYMP (0.56) | TYMPADORA2BADORA1ADORA2AP2RY12 | |
| SCHEMBL15994035 | 0.81 | TYMP (0.52) | TYMP | |
| SCHEMBL13785237 | 0.80 | TYMP (0.54) | TYMPADORA2BADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961757-B1 | CELL-PENETRATING OLIGONUCLEOTIDES | OLIGOMER SCIENCES AB (SE) | 2017-06-14 | — | — | EP | claimed |
| US-9463200-B2 | Cell-penetrating oligonucleotides | OLIGOMER SCIENCES AB (SE) | 2016-10-11 | — | — | US | disclosed |
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | ASTRAZENECA AB (SE) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | SLC29A1, SLC29A2, TYMP | TYMP 3/4885ADORA2B 37/4885ADORA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.